v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Summary
Compensation
Table (SCT)
Total for
CEO(1)
($)
Compensation
Actually
Paid (CAP)
to CEO(1)(2)
($)
Average
SCT
Total for
Other
NEOs(1)
($)
Average
CAP to
Other
NEOs(1)(2)
($)
Value of Initial Fixed $100
Investment Based On:
Net Income
($ in millions)
Revenue
(Company
Selected
Measure)
($ in millions)
Year
Zoetis TSR
($)
S&P 500
Pharmaceuticals
Index TSR
($)
202519,046,509 2,772,228 4,015,823 1,524,245 79.52 188.27 2,673 9,467 
202417,206,760 759,623 3,351,274 1,095,197 101.62 148.06 2,486 9,256 
202315,237,853 26,369,229 2,994,932 4,592,358 121.90 136.84 2,344 8,544 
202214,003,540 (15,709,790)2,931,816 (3,076,052)89.69 136.38 2,114 8,080 
202113,098,491 33,519,679 4,455,516 10,261,897 148.26 125.75 2,037 7,776 
        
Company Selected Measure Name Revenue        
Named Executive Officers, Footnote In all years shown Kristin C. Peck was our Chief Executive Officer. The other named executive officers (NEO) represent the following individuals: for 2025, Wetteny Joseph, Robert J. Polzer, Jamie Brannan and Roxanne Lagano; for 2024, Wetteny Joseph, Robert J. Polzer, Jamie Brannan, Roxanne Lagano, Heidi C. Chen, and Wafaa Mamilli; for 2023, Wetteny Joseph, Heidi C. Chen, Wafaa Mamilli and Robert J. Polzer; for 2022, Wetteny Joseph, Glenn C. David, Heidi C. Chen, and Wafaa Mamilli; and for 2021, Wetteny Joseph, Glenn C. David, Catherine A. Knupp, Roman Trawicki and Heidi C. Chen        
PEO Total Compensation Amount $ 19,046,509 $ 17,206,760 $ 15,237,853 $ 14,003,540 $ 13,098,491
PEO Actually Paid Compensation Amount $ 2,772,228 759,623 26,369,229 (15,709,790) 33,519,679
Adjustment To PEO Compensation, Footnote To calculate Compensation Actually Paid (“CAP”) the following amounts were deducted from and added to the Summary Compensation Table (“SCT”) total compensation:
CEO SCT Total to CAP Reconciliation:
Deductions from SCT Total(a)
Year
SCT Total
($)
Stock
Awards
($)
Options
Awards
($)
Additions to
SCT Total(b)
($)
Compensation
Actually Paid
($)
202519,046,509 (10,218,583)(3,406,229)(2,649,469)2,772,228 
202417,206,760 (9,562,347)(3,187,500)(3,697,290)759,623 
202315,237,853 (8,774,860)(2,924,967)22,831,203 26,369,229 
202214,003,540 (8,399,841)(2,799,966)(18,513,523)(15,709,790)
202113,098,491 (6,929,797)(2,309,970)29,660,955 33,519,679 
CEO Equity Component of CAP:
Year
Equity Type
Fair Value of
Current Year
Equity Awards at
End of Year
($)
Change in Value
of Prior Years’
Awards Unvested at
End of Year
($)
Change in Value
of Prior Years’
Awards That Vested
During the Year
($)
Equity Value
Included in CAP
($)
2025
Stock Options
1,885,667 (2,098,846)(1,165,649)(1,378,828)
Restricted Stock Units
2,764,067 (1,672,795)128,472 1,219,744 
Performance Award Units
4,152,539 (6,642,924)— (2,490,385)
Total
8,802,273 (10,414,565)(1,037,177)(2,649,469)
2024Stock Options1,599,375 (2,205,096)(40,922)(646,643)
Restricted Stock Units2,668,416 (867,090)5,906 1,807,232 
Performance Award Units2,859,270 (7,726,027)8,878 (4,857,879)
Total7,127,061 (10,798,213)(26,138)(3,697,290)
2023
Stock Options
3,971,133 1,923,431 372,068 6,266,632 
Restricted Stock Units
3,585,639 1,500,387 162,461 5,248,488 
Performance Award Units
8,054,738 3,060,551 200,795 11,316,083 
Total
15,611,510 6,484,369 735,324 22,831,203 
2022
Stock Options
1,528,648 (7,897,241)(931,398)(7,299,991)
Restricted Stock Units
2,049,978 (2,672,369)(234,149)(856,541)
Performance Award Units
2,460,116 (12,009,652)(807,455)(10,356,991)
Total
6,038,742 (22,579,262)(1,973,002)(18,513,523)
2021
Stock Options
5,709,571 5,052,274 33,020 10,794,866 
Restricted Stock Units
3,523,058 1,469,682 10,165 5,002,905 
Performance Award Units
8,916,215 4,932,126 14,842 13,863,183 
Total
18,148,844 11,454,083 58,027 29,660,955 
        
Non-PEO NEO Average Total Compensation Amount $ 4,015,823 3,351,274 2,994,932 2,931,816 4,455,516
Non-PEO NEO Average Compensation Actually Paid Amount $ 1,524,245 1,095,197 4,592,358 (3,076,052) 10,261,897
Adjustment to Non-PEO NEO Compensation Footnote
Average Other NEOs SCT Total to CAP Reconciliation:
Deductions from SCT Total(a)
Year
SCT Total
($)
Stock
Awards
($)
Options
Awards
($)
Additions to
SCT Total(b)
($)
Compensation
Actually Paid
($)
20254,015,823 (1,807,991)(602,728)(80,859)1,524,245 
20243,351,274 (1,236,913)(412,369)(606,795)1,095,197 
20232,994,932 (1,239,133)(413,112)3,249,671 4,592,358 
20222,931,816 (1,405,542)(468,570)(4,133,756)(3,076,052)
20214,455,516 (2,118,241)(366,105)8,290,727 10,261,897 
(a)These deductions are the amounts listed in the “Stock Awards” and “Option Awards” columns of the SCT and represent the grant date fair value of equity-based awards granted each year.
(b)Reflects the value of equity calculated in accordance with the SEC methodology for determining CAP for each year shown. The equity component for each year is detailed in the supplemental table below:
Average Other NEOs Equity Component of CAP:
Year
Equity Type
Fair Value of
Current Year
Equity Awards at
End of Year
($)
Change in Value
of Prior Years’
Awards Unvested at
End of Year
($)
Change in Value
of Prior Years’
Awards That Vested
During the Year
($)
Equity Value
Included in CAP
($)
2025
Stock Options
333,666 (264,533)(123,407)(54,274)
Restricted Stock Units
442,928 (232,129)(112,232)98,567 
Performance Award Units
734,704 (859,856)— (125,152)
Total
1,511,298 (1,356,518)(235,639)(80,859)
2024Stock Options177,330 (251,572)(2,688)(76,930)
Restricted Stock Units303,934 (131,626)(106,952)65,356 
Performance Awards Units324,800 (920,604)583 (595,221)
Total806,064 (1,303,802)(109,057)(606,795)
2023
Stock Options
560,869 169,611 46,139 776,619 
Restricted Stock Units
506,345 509,551 20,141 1,036,037 
Performance Award Units
1,137,439 284,615 14,962 1,437,015 
Total
2,204,652 963,777 81,242 3,249,671 
2022
Stock Options
255,817 (1,352,757)(446,281)(1,543,221)
Restricted Stock Units
343,039 (1,110,941)(112,191)(880,093)
Performance Award Units
411,640 (1,735,180)(386,902)(1,710,442)
Total
1,010,496 (4,198,878)(945,373)(4,133,756)
2021
Stock Options
904,905 1,796,558 22,234 2,723,696 
Restricted Stock Units
1,897,216 490,667 6,844 2,394,727 
Performance Award Units
1,413,054 1,749,257 9,993 3,172,304 
Total
4,215,175 4,036,482 39,071 8,290,727 
        
Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid (CAP) versus Zoetis TSR
The graph below compares the Compensation Actually Paid (CAP) of the CEO and the Other NEOs, to Zoetis’ TSR for the five fiscal years beginning with 2021. As the graph shows, the CAP to the CEO and Other NEOs is directionally aligned with the Company’s TSR.
CAP vs. TSR: Zoetis
3764
n
CEO Cap
n
Other NEO Avg. CAP
02_439034-3_icon_legends_charts_line3.jpg 
Zoetis TSR
        
Compensation Actually Paid vs. Net Income CAP versus Net Income
The graph below compares the CAP of the CEO and the Other NEOs, to Zoetis’ net income for the five fiscal years beginning with 2021. Net Income has steadily increased while the CEO and Other NEOs CAP has varied by year. Zoetis does not use net income as a metric in its compensation incentives.
CAP vs. Net Income
($ in millions)
4121
n
CEO Cap
n
Other NEO Avg. CAP
02_439034-3_icon_legends_charts_line3.jpg 
Net Income
        
Compensation Actually Paid vs. Company Selected Measure CAP versus Revenue (Company Selected Measure)
The graph below compares the CAP of the CEO and the Other NEOs, to Zoetis’ revenue for the five fiscal years beginning with 2021. Revenue has steadily increased while the CEO and Other NEOs’ CAP has varied by year. While revenue is a metric in Zoetis’ AIP, the weight of equity-based LTI — which primarily reflect stock price and relative TSR — exceeds the weight of our annual incentive in the total compensation for executives.
CAP vs. Revenue
($ in millions)
4640
n
CEO Cap
n
Other NEO Avg. CAP
02_439034-3_icon_legends_charts_line3.jpg 
Revenue
        
Total Shareholder Return Vs Peer Group Total Shareholder Return (TSR): Zoetis versus S&P 500 Pharmaceuticals Index
The graph below compares an initial investment in our common stock of $100 on December 31, 2020, versus the same investment in the S&P 500 Pharmaceuticals Index (assuming dividends, if any, were reinvested). It should be noted that the companies in the S&P 500 Pharmaceuticals index are not the same as those used for our compensation benchmarking, nor are they the same group of companies we use to determine Relative TSR for the company’s performance award unit metric, as described in the CD&A.
TSR: Zoetis vs. S&P 500 Pharmaceuticals Index
3430
02_439034-3_icon_legends_charts_line2.jpg 
Zoetis TSR
02_439034-3_icon_legends_charts_line1.jpg 
S&P 500 Pharmaceuticals TSR
        
Tabular List, Table
Most Important Performance Measures
Relative Total Shareholder Return(a)
Revenue(b)(c)
Adjusted Diluted EPS(b)
Free Cash Flow(b)
        
Total Shareholder Return Amount $ 79.52 101.62 121.90 89.69 148.26
Peer Group Total Shareholder Return Amount 188.27 148.06 136.84 136.38 125.75
Net Income (Loss) $ 2,673,000,000 $ 2,486,000,000 $ 2,344,000,000 $ 2,114,000,000 $ 2,037,000,000
Company Selected Measure Amount 9,467,000,000 9,256,000,000 8,544,000,000 8,080,000,000 7,776,000,000
PEO Name Kristin C. Peck        
Additional 402(v) Disclosure
The four items listed below represent the most important metrics we used to determine CAP for 2025 as further described in our CD&A within the sections titled “Annual Incentive Plan” and “Long-Term Incentives”:
Relative Total Shareholder Return is the 3-year performance metric used for Zoetis’ performance award units, which comprise 50% of the long-term incentive compensation of our NEOs, including the CEO. Total Shareholder Return (“TSR”) is the appreciation of share price, including dividends, during the performance period. Relative TSR is Zoetis’ TSR as compared to the TSR over the performance period of the “S&P 500 Health Care Group”, which we define as the companies comprising the S&P 500 Health Care index as of the beginning of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded.
(b)Revenue, Adjusted Diluted EPS and Free Cash Flow refer to the measures used to assess performance in determining the funding for our Annual Incentive Plan (AIP) and exclude the impacts of foreign exchange and certain other adjustments as described in the CD&A.
(c)Three-year average annual Operational Revenue Growth is a performance goal for our current year performance award units. 		       
Measure:: 1          
Pay vs Performance Disclosure          
Name Relative Total Shareholder Return        
Measure:: 2          
Pay vs Performance Disclosure          
Name Revenue        
Measure:: 3          
Pay vs Performance Disclosure          
Name Adjusted Diluted EPS        
Measure:: 4          
Pay vs Performance Disclosure          
Name Free Cash Flow        
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (2,649,469) $ (3,697,290) $ 22,831,203 $ (18,513,523) $ 29,660,955
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 8,802,273 7,127,061 15,611,510 6,038,742 18,148,844
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (10,414,565) (10,798,213) 6,484,369 (22,579,262) 11,454,083
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,037,177) (26,138) 735,324 (1,973,002) 58,027
PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (10,218,583) (9,562,347) (8,774,860) (8,399,841) (6,929,797)
PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,406,229) (3,187,500) (2,924,967) (2,799,966) (2,309,970)
PEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 1,885,667 1,599,375 3,971,133 1,528,648 5,709,571
PEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (2,098,846) (2,205,096) 1,923,431 (7,897,241) 5,052,274
PEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (1,165,649) (40,922) 372,068 (931,398) 33,020
PEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (1,378,828) (646,643) 6,266,632 (7,299,991) 10,794,866
PEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 2,764,067 2,668,416 3,585,639 2,049,978 3,523,058
PEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (1,672,795) (867,090) 1,500,387 (2,672,369) 1,469,682
PEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 128,472 5,906 162,461 (234,149) 10,165
PEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 1,219,744 1,807,232 5,248,488 (856,541) 5,002,905
PEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 4,152,539 2,859,270 8,054,738 2,460,116 8,916,215
PEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (6,642,924) (7,726,027) 3,060,551 (12,009,652) 4,932,126
PEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 0 8,878 200,795 (807,455) 14,842
PEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (2,490,385) (4,857,879) 11,316,083 (10,356,991) 13,863,183
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (80,859) (606,795) 3,249,671 (4,133,756) 8,290,727
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,511,298 806,064 2,204,652 1,010,496 4,215,175
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,356,518) (1,303,802) 963,777 (4,198,878) 4,036,482
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (235,639) (109,057) 81,242 (945,373) 39,071
Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,807,991) (1,236,913) (1,239,133) (1,405,542) (2,118,241)
Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (602,728) (412,369) (413,112) (468,570) (366,105)
Non-PEO NEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 333,666 177,330 560,869 255,817 904,905
Non-PEO NEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (264,533) (251,572) 169,611 (1,352,757) 1,796,558
Non-PEO NEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (123,407) (2,688) 46,139 (446,281) 22,234
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Stock Options [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (54,274) (76,930) 776,619 (1,543,221) 2,723,696
Non-PEO NEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 442,928 303,934 506,345 343,039 1,897,216
Non-PEO NEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (232,129) (131,626) 509,551 (1,110,941) 490,667
Non-PEO NEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (112,232) (106,952) 20,141 (112,191) 6,844
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Restricted Stock Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 98,567 65,356 1,036,037 (880,093) 2,394,727
Non-PEO NEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 734,704 324,800 1,137,439 411,640 1,413,054
Non-PEO NEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards (859,856) (920,604) 284,615 (1,735,180) 1,749,257
Non-PEO NEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards 0 583 14,962 (386,902) 9,993
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Performance Award Units [Member]          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Equity Awards $ (125,152) $ (595,221) $ 1,437,015 $ (1,710,442) $ 3,172,304